Claims for Patent: 7,074,408

Summary for Patent: 7,074,408

Title:	Use of integrin antagonists to inhibit angiogenesis
Abstract:	The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration. and for inhibiting angiogenesis. In particular, the invention provides compositions comprising ADAM disintegrin domains and methods for using said compositions. In preferred embodiments the methods and compositions of the invention are used to inhibit angiogenesis and to treat diseases or conditions mediated by angiogenesis.
Inventor(s):	Fanslow, III; William C. (Seattle, WA), Cerretti; Douglas P. (Seattle, WA), Poindexter; Kurt M. (Seattle, WA), Black; Roy A. (Seattle, WA)
Assignee:	Immunex Corporation (Seattle, WA)
Application Number:	09/792,200
Patent Claims:	1. A method of inhibiting angiogenesis in a mammal in need of such treatment, comprising administering to the mammal an inhibition-effective amount of an ADAM-20 disintegrin domain polypeptide, wherein the ADAM-20 disintegrin domain polypeptide comprises an amino acid sequence selected from the group consisting of: (a) amino acids 34 91 of SEQ ID NO:12; and (b) amino acids 23 305 of SEQ ID NO:12, wherein the ADAM-20 disintegrin polypeptide retains inhibition of angiogenesis activity. 2. The method of claim 1, wherein the mammal is afflicted with a malignant condition. 3. The method of claim 1, wherein the ADAM-20disintegrin domain is in the form of a multimer. 4. The method of claim 3, wherein the multimer is a dimer or trimer. 5. The method of claim 3, wherein the multimer comprises an Fc polypeptide or a leucine zipper. 6. The method of claim 1, wherein the ADAM-20 disintegrin domain is from a human ADAM-20. 7. The method of claim 1, wherein the ADAM-20 disintegrin domain polypeptide has been produced by culturing a recombinant cell which comprises a nucleic acid that encodes the ADAM-20 disintegrin domain polypeptide under conditions permitting expression of the ADAM-20 disintegrin domain polypeptide, and recovering the ADAM-20 disintegrin domain polypeptide. 8. The method of claim 1, wherein the ADAM-20 disintegrin domain polypeptide is present in a composition comprising a pharmaceutically acceptable carrier. 9. The method of claim 1, wherein the mammal has a disease or condition mediated by angiogenesis, wherein the disease or condition is a solid tumor. 10. The method of claim 1, wherein the method further comprises treating the mammal with radiation. 11. The method of claim 1, wherein the method further comprises treating the mammal with a second therapeutic agent. 12. The method of claim 11, wherein the second therapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, vinca alkaloids and other plant-derived chemotherapeutics, antitumor antibiotics, antitumor enzymes, topoisomerase inhibitors, platinum analogs, adrenocortical suppressants, hormones and antihormones, antibodies, immunotherapeutics, radiotherapeutics, and biological response modifiers. 13. The method of claim 11, wherein the second therapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, bleomycin, carboplatin, fluorouracil, 5-fluorouracil, 5-fluorodeoxyuridine, methotrexate, taxol, asparaginase, vincristine, vinblastine, mechloretamine, melphalan, 5-fluorodeoxyuridine, lymphokines and cytokines interleukins, interferons, TNF, chlorambucil, busulfan, carmustine, lomustine, semustine, streptozocin, dacarbazine, cytarabine, mercaptopurine, thioguanine, vindesine, etoposide, teniposide, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, mitomycin, L-asparaginase, hydroxyurea, methylhydrazine, mitotane, tamoxifen, fluoxymesterone, and COX-2 inhibitors. 14. The method of claim 11, wherein the second therapeutic agent is a polypeptide, including soluble forms thereof, selected from the group consisting of Flt3 ligand, CD40 ligand, interleukin-2, interleukin-12, 4-1BB ligand, anti-4-1BB antibodies, TRAIL, TNF antagonists and TNF receptor antagonists including TNFR/Fc, Tek antagonists, TWEAK antagonists and TWEAK-R antagonists including TWEAK-R/Fc, VEGF antagonists including anti-VEGF antibodies, VEGF receptor antagonists, CD148 binding proteins, and nectin-3 antagonists. 15. The method of claim 1, wherein the ADAM-20 disintegrin domain is administered parenterally. 16. The method of claim 1, wherein the mammal is afflicted with retinoblastoma. 17. The method of claim 16, wherein the retinoblastoma is characterized by ocular neovascularization. 18. The method of claim 7, wherein the recombinant cell is a prokaryotic cell. 19. The method of claim 18, wherein the prokaryotic cell is an E. coli cell. 20. The method of claim 7, wherein the recombinant cell is a plant cell. 21. The method of claim 7, wherein the recombinant cell is a fungal cell. 22. The method of claim 7, wherein the recombinant cell is a yeast cell. 23. The method of claim 7, wherein the recombinant cell is an animal cell. 24. The method of claim 23, wherein the animal cell is an insect cell. 25. The method of claim 23, wherein the animal cell is a mammalian cell. 26. The method of claim 25, wherein the mammalian cell is selected from the group consisting of COS-1 cells and COS-7 cells. 27. The method of claim 9, wherein the solid tumor is selected from the group consisting of sarcomas and carcinomas. 28. A method of inhibiting angiogenesis in a mammal in need of such treatment, comprising administering to the mammal an inhibition-effective amount of a fusion polypeptide comprising the ADAM-20 disintegrin domain polypeptide of claim 1, wherein said fusion polypeptide retains inhibition of angiogenesis activity. 29. The method of claim 28, wherein said fusion polypeptide consists of the amino acid sequence of SEQ ID NO:12.

Details for Patent 7,074,408

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2020-02-25